Diagnosis & Disease Information

Data Support PCa Vaccine’s Mechanism of Action

Phase 3 trial data presented at the American Association of Cancer Research annual meeting support the mechanism of action of Provenge (sipuleucel-T), a novel investigative immunotherapy for advanced prostate cancer, according to a statement issued by Dendreon Corp., of Seattle, which is developing the treatment.

Focal Ablation May Treat PCa Relapses

TAMPA, Fla.—Magnetic resonance (MR)-guided ablative therapy using laser thermal energy or cryoablation could provide another option for treating locally recurrent prostate cancer after radical retropubic prostatectomy (RRP), results from a pilot study suggest.

Next post in Bladder Cancer